Ipsen to Acquire Oncology Assets from Merrimack Pharmaceuticals
- Transaction includes U.S. commercialization rights for ONIVYDE® for metastatic pancreatic cancer in adult patients
- $575 million cash at closing and additional
potential payments for new indications
- Transaction bolsters Ipsen’s growing oncology presence and leverages Oncology infrastructure in the U.S.
Ipsen (Euronext: IPN; ADR: IPSEY) today announced that it has entered into a definitive agreement to acquire global oncology assets from Merrimack Pharmaceuticals (NASDAQ: MACK), including its key marketed product ONIVYDE® (irinotecan liposome injection) for the treatment of patients with metastatic adenocarcinoma of the pancreas after disease progression following gemcitabine-based therapy, in combination with fluorouracil and leucovorin. Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection.
 Onivyde® is indicated in combination with fuorouracil and leucovorin after disease progression following gemcitabine-based therapy